- Home
- CBIO vs DMAC Comparison
CBIO vs DMAC Comparison
Compare CBIO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- DMAC
- Stock Information
- Founded
- CBIO 2003
- DMAC 2000
- Country
- CBIO United States
- DMAC United States
- Employees
- CBIO N/A
- DMAC N/A
- Industry
- CBIO
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CBIO
- DMAC Health Care
- Exchange
- CBIO Nasdaq
- DMAC Nasdaq
- Market Cap
- CBIO 308.0M
- DMAC 310.1M
- IPO Year
- CBIO N/A
- DMAC N/A
- Fundamental
- Price
- CBIO $14.29
- DMAC $5.71
- Analyst Decision
- CBIO Strong Buy
- DMAC Strong Buy
- Analyst Count
- CBIO 5
- DMAC 3
- Target Price
- CBIO $25.60
- DMAC $12.33
- AVG Volume (30 Days)
- CBIO 97.6K
- DMAC 310.7K
- Earning Date
- CBIO 07-31-2025
- DMAC 08-12-2025
- Dividend Yield
- CBIO N/A
- DMAC N/A
- EPS Growth
- CBIO N/A
- DMAC N/A
- EPS
- CBIO N/A
- DMAC N/A
- Revenue
- CBIO N/A
- DMAC N/A
- Revenue This Year
- CBIO N/A
- DMAC N/A
- Revenue Next Year
- CBIO N/A
- DMAC N/A
- P/E Ratio
- CBIO N/A
- DMAC N/A
- Revenue Growth
- CBIO N/A
- DMAC N/A
- 52 Week Low
- CBIO $10.83
- DMAC $3.19
- 52 Week High
- CBIO $21.40
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- DMAC 57.83
- Support Level
- CBIO $13.50
- DMAC $5.90
- Resistance Level
- CBIO $16.00
- DMAC $6.16
- Average True Range (ATR)
- CBIO 0.79
- DMAC 0.38
- MACD
- CBIO 0.16
- DMAC -0.03
- Stochastic Oscillator
- CBIO 39.68
- DMAC 61.02
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.